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Abstract 
Purpose: To formulate trimethyl chitosan-functionalized retinoic acid-encapsulated solid lipid 
nanoparticles for the effective treatment of glioma. 
Methods: Retinoic acid-loaded solid lipid nanoparticles (R-SLNs) were prepared using homogenization 
followed by sonication. R-SLN surfaces were functionalized electrostatically with trimethyl chitosan as a 
nanocarrier (TR-SLNs) with enhanced anti-cancer activity. They were evaluated by dynamic light 
scattering (DLS), scanning electron microscopy, in vitro drug release, and cell cytotoxicity and apoptosis 
studies. 
Results: Morphological images showed spherical and uniformly dispersed nanoparticles. A sustained 
monophasic release pattern was observed throughout the study period. Furthermore, the anti-cancer 
effect of TR-SLNs was demonstrated by increased cell killing activity compared with the free drug (p < 
0.01); negligible cytotoxicity was observed with blank carriers. Apoptosis assay showed increased cell 
populations in early/late apoptotic and necrotic phases. 
Conclusion: This study showed the potential application of surface-modified solid lipid nanoparticles for 
the effective treatment of brain cancer. 
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Glioblastoma is a harmful and often fatal brain 
malignancy, with approximately 23, 000 cases 
diagnosed in adults in the US each year [1,2]. 
Glioblastoma is regarded as a Grade IV tumor by 
the World Health Organization (WHO) [3,4]. The 
blood–brain barrier (BBB) provides a uniquely 
privileged immune environment that remains 
impenetrable to many small and large molecule 
therapeutics used for treatment [5]. 
 
Lipid-based carriers are within the submicron 
range in size (i.e., 100–300 nm); therefore, we 
developed a lipid-based carrier to deliver 
molecular therapeutics across the BBB to tumors 
[6,7]. Additionally, solid lipid nanoparticles 
(SLNs) have a solid lipid core that can effectively 
incorporate hydrophobic drugs. Lipid 
nanoparticles are non-toxic and biocompatible, 
with a good loading capacity, resulting in 
increased solubility and stability of the loaded 
drugs; sustained delivery of hydrophobic drugs 
using lipid nanoparticles has been reported [8,9]. 
We designed surface-modified SLNs, which have 
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been used as a system to successfully deliver 
drugs across the BBB to tumor tissues with high 
specificity [10]. 
 
Chitosan (CS), a cationic natural polymer, 
exhibits excellent biomedical properties for the 
sustained release of therapeutic agents; it is 
biodegradable, biocompatible, modifiable, and 
non-toxic [11]. Chitosan, N-deacetylated chitin, 
can be derivatized by N-methylation to form N, N, 
N-trimethyl chitosan (TMC). CS has several 
moieties that can readily be methylated to 
change its form from a trimethyl group into a 
polysaccharide backbone, which improves its 
aqueous solubility over all pH ranges because of 
its polyelectrolytic cationic nature, whereas CS is 
most soluble in acidic environments at pH < 6 
[12]. TMC also possesses mucoadhesive and 
absorption-enhancing properties because it can 
transiently open tight junctions between epithelial 
cells without cytotoxicity [13]. Thus, TMC has 
potential in targeted drug-delivery applications. 
 
Retinoic acid (RA), a derivative of vitamin A, is a 
potential anti-cancer agent [14]. RA action is 
mediated by binding of RA receptors present in 
the nucleus of carcinoma cells, which then bind 
to regulatory regions of specific target genes, 
followed by growth inhibition and apoptosis in 
brain carcinoma cells. However, the poor 
aqueous solubility of RA is a major hurdle for its 
intravenous (i.v.) administration; therefore, RA 
incorporated into surface-modified lipid-based 
carriers could be a promising means to 
overcome its solubility limitations [15,16]. 
 
In this study, we developed stable RA-loaded 
SLNs (R-SLNs) and subsequently investigated 
their surface modification with TMC (TR-SLNs). 
Furthermore, we performed several 
physicochemical characterizations, 
morphological imaging, and assessed the in vitro 
release patterns of R-SLNs and TR-SLNs. 
Cytotoxicity and annexin V/propidium iodide (PI) 
staining studies were performed in U87MG cells 
that showed improved anti-cancer efficacy in 
delivering RA across the BBB to inhibit brain 







Compritol® 888 ATO and Tween 80 were from 
BASF (Ludwigshafen, Germany). Retinoic acid 
was purchased from TCI (Korea). Cholesterol 
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) were purchased from 
Sigma-Aldrich (UK). An annexin V/PI staining 
apoptosis kit was obtained from BD Biosciences 
(UK). U87MG cells were purchased from the 
American Type Culture Collection (ATCC; USA) 
and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Hyclone, Beijing, China), 
supplemented with 10 % fetal bovine serum 
(FBS; Hyclone) in a 5 % CO2 atmosphere at 37 
°C. 
 
Preparation of TMC 
 
TMC was synthesized by reductive methylation 
according to a previous report with some 
modifications [17]. Briefly, 2 g chitosan, 1.3 g 
sodium azide, 4 mL sodium hydroxide (10 % 
w/v), and 3.5 mL methyl iodide were added and 
stirred at 50 °C for 2 h. Next, 150 mL of distilled 
water (DW) was added and stirring was 
continued for 1 h before being dialyzed against 
DW (3, 500 Da cut-off) overnight. A precipitate 
was formed by adding a large volume of acetone; 
it was washed with sodium hydroxide. The 
precipitate was suspended in water and dialyzed 
for 24 h, followed by freeze drying. 
 
Preparation of nanoparticles 
 
SLNs were prepared by a homogenization 
method followed by probe sonication (Figure 1). 
The lipid phase, consisting of Compritol® 888 
(250 mg), stearic acid (50 mg), and cholesterol 
(30 mg), was heated and melted. RA (10 mg) 
was then dispersed in the hot lipid phase, after 
which a preheated aqueous phase (250 mg), and 
later Tween 80, was added to the lipophilic 
phase and homogenized using an Ultra-Turrax® 
homogenizer (3 min, 13,000 rpm). The resulting 
pre-emulsion was then sonicated using a probe 
sonicator for 5 min. The synthesized TMC was 
added to the surface of the SLNs by adding at a 
ratio of 30: 1 (w/w) and stirred for 6 h. Finally, the 
reaction was centrifuged (11, 000 rpm, 15 min). 
The resulting TMC-SLNs were lyophilized and 
stored at 4 °C. 
 
Dynamic light scattering (DLS) 
 
The mean particle size, polydispersity index 
(PDI), and zeta potential (ZP) of the TR-SLNs 
were measured using an ELSZ-1000 (Photal 
Otsuka Electronics, Japan), based on the DLS 
method. Data are expressed as means ± 




Field emission scanning electron microscopy 
(FE-SEM) of TR-SLNs was performed (JSM 
electron microscope; JEOL, Japan).  
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Figure 1: Schematic representation of the preparation of TMC-entangled RA-loaded solid lipid 
nanoparticles (TR-SLNs) 
 
The freeze-dried samples were spread on carbon 
tape over a stub and vacuum-dried. Then, a gold 
coating was applied using an ion-sputtering 
device. The gold-coated samples were vacuum-
dried and examined under the electron 
microscope. 
 
Determination of encapsulation efficiency 
(EE) 
 
EE was estimated by high-performance liquid 
chromatography (HPLC). Briefly, 1 mL of the 
formulation was centrifuged (5, 000 rpm, 30 min, 
25 °C). The TMC-coated RA-loaded SLNs were 
then dissolved in tetrahydrofuran and diluted in 
the mobile phase. The mobile phase consisted of 
acetonitrile, DW, and phosphoric acid (75: 20: 
0.1) at a flow rate of 1 mL/min. This dispersion 
was filtered through in a 0.45-µM membrane filter 
(Millipore, US) and analyzed by HPLC at a 
wavelength of 340 nm. The encapsulation 
efficiency (E %) was calculated using Equation 1: 
 
E (%) = {(Rt − Rf)/Rt} × 100   
    
where Rt and Rf are the total amount of RA and 
amount of free RA, respectively. 
In vitro drug release studies 
 
The in vitro release study was performed using a 
dialysis method. RT-SLNs (1 mL) were placed in 
a dialysis bag (MW cut-off, 10 kDa), which was 
then suspended in PBS buffer, pH 7.4, as the 
release medium. Samples were kept in a shaking 
water bath at 37 °C with gentle stirring (100 rpm). 
At stipulated time intervals, the buffer (10 mL) 
was replaced with fresh medium to maintain sink 
conditions, and the % drug released was 
analyzed using the HPLC-UV system described 




Briefly, 1.5 × 104 U87MG cells were seeded in a 
96-well plate in 100 µL of medium and incubated 
for 24 h. Then, they were treated with various 
formulations (RA, R-SLNs, and TR-SLNs) at 
increasing concentrations, ranging from 0.01 to 
25 µg/mL, and with blank carrier SLNs and T-
SLNs (0.001 to 500 µg/mL). The formulations 
were incubated for 24 h. Then, cells were 
washed with PBS and treated with MTT solution 
(5 mg/mL) and incubated for a further 4 h. The 
resulting formazan crystals were then dissolved 
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in 0.1 mL of DMSO. The plate with the mixture 
was gently shaken before measuring the 
absorbance at 570 nm on a microplate reader. 




U87MG cells were seeded at a density of 2 × 
105 cells/well in a 6-well plate and incubated for 
24 h. The cells were treated with free RA, R-
SLNs, and TR-SLNs for 24 h. Then, the cells 
were trypsinized, washed, collected in PBS, 
and stained with annexin-V and PI for 15 min. 
Finally, the cells were assessed using a 





Student’s t-test was used to compare 
differences between groups. P values < 0.05 
were considered to indicate statistical 
significance. Statistical evaluations were 
performed using the Mann–Whitney U test. 
SPSS software (ver. 20.0; SPSS Inc., IL, USA) 
was used. Experiments were performed at least 





Characteristics of R-SLNs and TR-SLNs 
 
The mean particle size was 148 ± 2.41, the 
polydispersity (PDI) was 0.124, and the ZP was 
−21.2 ± 1.47. After the TMC coating was 
applied to the surface of SLNs, the particle size 
was increased to 214 ± 3.45 nm and the PDI 
was 0.214 ± 0.01, with a marked increase in 
charge due to the strong positive nature of TMC 
compared with bare SLNs (Figure 2). 
 
RA caused a marked increase in the viscosity, 
resulting in an increased nanoparticle size. 
These results confirmed the presence of TMC on 
the surface of the nanocarriers. Lipid 
nanocarriers have recently gained attention for 
improving the delivery of hydrophobic drugs due 
to the high affinity of these small molecules for 
the lipid core. The EE of retinoic acid was high 
(86.4 ± 0.16 % for R-SLNs; 92.3 ± 0.08 % for TR-
SLNs) with increased cholesterol amounts due to 
extra voids and rigidity between lipid molecules, 
thus reducing the ‘leakage’ of the small molecule 
from the solid lipid core of the SLNs. Figure 3 
shows SEM images of TR-SLNs: they appeared 
to be smooth and spherical with a uniformly 
distributed size, indicating that the shape of the 




Figure 3: SEM image of TR-SLNs 
 
           Figure 2: DLS characteristic images of (a) R-SLNs and TR-SLNs (PS) and (b) ZP 
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In vitro release  
 
As shown in Figure 4, R-SLNs and TR-SLNs 
exhibited interesting release behaviors. Initially, 
R-SLNs showed a biphasic release pattern with 
an initial burst release over the first 10 h, with 
almost 42.8 ± 3.74 % of the drug being released, 
followed by sustained release for over 2 d, with 
approximately 58.2 ± 2.58 % of the drug being 
released. The TR-SLNs showed a monophasic 
release behavior throughout the study period, 
with 38.4 ± 1.14 % of the drug being released. 
 
 
Figure 4: Drug release of RA from R-SLNs and TR-
SLNs in PBS. The experiment was performed in 
triplicate (n = 3) 
 
The initial burst release suggests the presence of 
small molecules adsorbed on the surface of the 
lipid nanoparticles, whereas the slower release 
suggests small molecules diffusing from the inner 
core of the lipid nanoparticles. The presence of 
TMC on the surface of the nanoparticle reflects 
the reduced, slower, and sustained release of the 




The in vitro effects of RA, R-SLNs, TR-SLNs, 
and blank carriers on cell viability were 
investigated in U87MG cells 3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium 
bromide using the MTT assay. As seen in Figure 
5, cell viabilities with unloaded SLN and T-SLNs 
were very high, with 85 % viability even at 24-h 
incubation when tested with various 
concentrations. 
 
Figure 6 shows that free RA was strongly 
cytotoxic at 10 µg/mL, with cell viability reduced 
to 62.2 ± 2.41 % after 24 h. The formulations 
exhibited concentration-dependent toxicity at 
different concentrations (0.01, 0.1, 1, 10, and 25 
µg/mL) throughout the study period. 
 
 
Figure 5: Cytotoxicity of blank SLNs and T-SLNs at 
different concentrations (n = 6) 
  
The surface-modified TR-SLNs exerted an in 
vitro anti-tumor inhibitory effect of 48.2 ± 2.84 % 
at 10 µg/mL and 32.4 ± 3.5 % at 25 µg/mL, which 
was higher than those observed with free drug 
and R-SLNs at all tested concentrations (p < 
0.01). The increased cytotoxicity with time 
suggests that the amount of drug released from 
the lipid core would increase with the prolonged 
circulation of TR-SLNs. 
 
 
Figure 6. Cytotoxicity assay of free-drug RA, R-SLNs, 
and TR-SLNs at different concentrations (n = 6) 
 
These results are similar to those of the blank 
carrier, indicating a negligible amount of 
cytotoxicity. The differences in cytotoxicity 
induced by the free drug and final formulations 
were significant. 
 
Annexin V/PI staining 
 
As shown in Figure 7, the apoptosis induced by 
RA, R-SLNs, and TR-SLNs was analyzed by flow 
cytometry.  
 
Liu et al 
Trop J Pharm Res, August 2017; 16(8): 1770  
 
 
Figure 7: (a) Qualitative and (b) quantitative analysis of annexin V/PI staining of free RA, R-SLNs, and TR-SLNs 
in U87MG cells by flow cytometry 
 
Of the cells treated with free RA (10 µg/mL), 
11.91 ± 1.47 % were in early apoptosis, while 
16.57 ± 2.4 % were in late apoptosis/early 
necrosis. Similarly, when treated with R-SLNs, 
6.5 ± 2.8 % of cells were in early apoptosis and 
12.26 ± 0.21 % were in late apoptosis. 
Interestingly, when the cells were treated with 
TR-SLNs, the cell populations in all phases were 
increased markedly, with 18.07 ± 0.1 %, 25.44 ± 
1.2 %, and 13.35 ± 2.7 % in the early and late 
apoptotic, and necrotic phases, respectively, 
compared with the control group. 
 
These results suggest that free RA, R-SLNs, and 
TR-SLNs also induced apoptosis at 10 µg/mL 
with a 24-h incubation time. These data are 
consistent with the cytotoxic data confirming the 




Glioblastoma is one of the most aggressive, 
prevalent, and fatal brain malignancies, with over 
8,000 cases diagnosed in the US per year [18]. 
RA-loaded SLNs represent an alternative 
treatment for this brain cancer. RA is a 
metabolite of vitamin A and has many 
physiological effects in cancer and skin diseases 
[19]. However, due to its poor solubility in the 
aqueous phase, a drug delivery system is 
needed; in this study, we encapsulated RA in 
SLNs. SLNs have gained attention as a 
particulate system to improve the delivery and 
stability of drugs [20,21]. 
 
RA-loaded SLNs were prepared by high-
pressure homogenization with a mean particle 
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size of 148 ± 2.41 nm, a PDI of 0.124, and a ZP 
of −21.2 ± 1.47. The size of the particle was 
increased versus bare SLNs after coating with 
TMC on the surface: 214 ± 3.45 nm and a PDI of 
0.214 ± 0.01, with a marked increase in charge 
due to the strongly positive nature of TMC. 
According to a previous study [22], the amount of 
surfactant added in SLN dispersions is important 
in enhancing the drug-loading efficiency. The 
initial burst release is due to some of the drug 
molecules being adsorbed on the surface of the 
SLN particles, whereas the prolonged circulation 
pattern of TR-SLNs indicates drug diffusion from 
the inner matrix of the lipid core (~38 %). 
 
Cytotoxic effects in U87MG cells were 
investigated using the MTT assay. Increased 
cytotoxicity of RA-loaded SLNs was observed 
compared with free RA. The results 
demonstrated that the cationic polymer-
functionalized lipid nanocarrier was more 
cytotoxic than R-SLNs, resulting in 
concentration-dependent toxicity. Increased 
cytotoxicity in conjunction with increased 
concentration indicates an increased amount of 
drug released from the lipid matrix, suggesting a 
sustained release effect of TR-SLNs. These 
results indicated that free RA was not 
significantly more cytotoxic than R-SLN, and the 
blank SLNs exhibited no significant effect on cell 
viability. Furthermore, apoptosis induction was 
detected by annexin V/PI staining with flow 
cytometry. After the cells were treated with TR-
SLNs, significant increases in early and late 
necrosis and apoptosis were observed when 
compared with the control. These data suggest 
greater activity of SLNs, in which RA is loaded 
with the lipid matrix of the SLNs, enabling 




A novel nanocarrier system, RA-loaded surface-
modified TMC-coated SLNs has been developed 
using a homogenization and sonication method. 
The spherical, uniformly distributed nano-sized 
particles (TR-SLNs) demonstrate sustained 
release behavior. TMC provides excellent 
protection to minimize the initial burst release 
and acts as a suitable carrier to improve the 
bioavailability of RA. The findings also show that 
the developed product exhbits anti-cancer 
activity. Thus, the optimized TR-SLNs are a 
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